Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Miromatrix to Report First Quarter 2023 Financial Results By: Miromatrix Medical Inc. via GlobeNewswire April 27, 2023 at 18:00 PM EDT EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13738056. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/ About MiromatrixMiromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com. Investor ContactGreg Chodaczek347-620-7010 ir@miromatrix.com Media Contact:press@miromatrix.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Miromatrix to Report First Quarter 2023 Financial Results By: Miromatrix Medical Inc. via GlobeNewswire April 27, 2023 at 18:00 PM EDT EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13738056. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/ About MiromatrixMiromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com. Investor ContactGreg Chodaczek347-620-7010 ir@miromatrix.com Media Contact:press@miromatrix.com
EDEN PRAIRIE, Minn., April 27, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13738056. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/ About MiromatrixMiromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com. Investor ContactGreg Chodaczek347-620-7010 ir@miromatrix.com Media Contact:press@miromatrix.com